Molecular Mechanisms and Clinical Applications of MiR-22 in Regulating Malignant Progression in Human Cancer (Review)

Overview

Journal Int J Oncol

Specialty Oncology

Date 2016 Dec 22

PMID 28000852

Citations 54

Authors

Jingyu Wang

Yuan Li

Meiman Ding

Honghe Zhang

Xiaoming Xu

Jinlong Tang

Affiliations

Soon will be listed here.

Abstract

miRNAs (microRNAs) have been validated to play fateful roles in the occurrence and development of cancers by post-transcriptionally targeting 3'-untranslated regions of the downstream gene mRNAs to repress mRNA expression. Mounting investigations forcefully document that not only does miR‑22 biologically impinge on the processes of senescence, energy supply, angiogenesis, EMT (epithelial-mesenchymal transition), proliferation, migration, invasion, metastasis and apoptosis, but also it genetically or epigenetically exerts dual (inhibitory/promoting cancer) effects in various cancers via CNAs (copy number alterations), SNPs (single nucleotide polymorphisms), methylation, acetylation and even more momentously hydroxymethylation. Additionally, miR‑22 expression may fluctuate with cancer progression in the body fluids of cancer patients and miR‑22 could amplify its inhibitory or promoting effects through partaking in positive or negative feedback loops and interplaying with many other related miRNAs in the cascade of events, making it possible for miR‑22 to be a promising and complementary or even independent cancer biomarker in some cancers and engendering profound influences on the early diagnosis, therapeutics, supervising curative effects and prognosis.

Citing Articles

Deletion of 17p in cancers: Guilt by (p53) association.

van Kampen F, Clark A, Soul J, Kanhere A, Glenn M, Pettitt A Oncogene. 2025; 44(10):637-651.

PMID: 39966556 PMC: 11876076. DOI: 10.1038/s41388-025-03300-8.

Pivotal role of the endoplasmic reticulum stress-related XBP1s/miR-22/SIRT1 axis in acute myeloid leukemia apoptosis and response to chemotherapy.

Philippe C, Jaud M, Feral K, Gay A, Van Den Berghe L, Farce M Leukemia. 2024; 38(8):1764-1776.

PMID: 38909090 PMC: 11286524. DOI: 10.1038/s41375-024-02321-8.

Unsaturated Fatty Acid Synthesis Is Associated with Worse Survival and Is Differentially Regulated by and Tumor Suppressor microRNAs in Neuroblastoma.

Sheeter D, Garza S, Park H, Benhamou L, Badi N, Espinosa E Cancers (Basel). 2024; 16(8).

PMID: 38672672 PMC: 11048984. DOI: 10.3390/cancers16081590.

Targeting PI3K/Akt in Cerebral Ischemia Reperfusion Injury Alleviation: From Signaling Networks to Targeted Therapy.

Zheng T, Jiang T, Ma H, Zhu Y, Wang M Mol Neurobiol. 2024; 61(10):7930-7949.

PMID: 38441860 DOI: 10.1007/s12035-024-04039-1.

Current evidence regarding the cellular mechanisms associated with cancer progression due to cardiovascular diseases.

Attachaipanich T, Chattipakorn S, Chattipakorn N J Transl Med. 2024; 22(1):105.

PMID: 38279150 PMC: 10811855. DOI: 10.1186/s12967-023-04803-2.

References

Pandey A, Zhang Y, Zhang S, Li Y, Tucker-Kellogg G, Yang H . TIP60-miR-22 axis as a prognostic marker of breast cancer progression. Oncotarget. 2015; 6(38):41290-306. PMC: 4747406. DOI: 10.18632/oncotarget.5636. View

Ahmad H, Muiwo P, Ramachandran S, Pandey P, Gupta Y, Kumar L . miR-22 regulates expression of oncogenic neuro-epithelial transforming gene 1, NET1. FEBS J. 2014; 281(17):3904-19. DOI: 10.1111/febs.12926. View

Shin Y, Yun J, Lee O, Han H, Lim S, An J . Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion. Cancer Res Treat. 2014; 46(2):178-85. PMC: 4022827. DOI: 10.4143/crt.2014.46.2.178. View

Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces D . Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep. 2013; 6(1):231-244. PMC: 3976649. DOI: 10.1016/j.celrep.2013.11.044. View

Li S, Hu R, Wang C, Guo F, Li X, Wang S . miR-22 inhibits proliferation and invasion in estrogen receptor α-positive endometrial endometrioid carcinomas cells. Mol Med Rep. 2014; 9(6):2393-9. DOI: 10.3892/mmr.2014.2123. View

Budd W, J Seashols-Williams S, Clark G, Weaver D, Calvert V, Petricoin E . Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis. PLoS One. 2015; 10(11):e0142373. PMC: 4636224. DOI: 10.1371/journal.pone.0142373. View

Yang M, Jiang N, Cao Q, Sun Q . EDD1 predicts prognosis and regulates gastric cancer growth in vitro and in vivo via miR-22. Biol Chem. 2016; . DOI: 10.1515/hsz-2015-0279. View

Ting Y, Medina D, Strair R, Schaar D . Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression. Biochem Biophys Res Commun. 2010; 394(3):606-11. DOI: 10.1016/j.bbrc.2010.03.030. View

Choi J, Hwang Y, Kim H, Khanal T, Do M, Jin S . Saponins from the roots of Platycodon grandiflorum suppresses TGFβ1-induced epithelial-mesenchymal transition via repression of PI3K/Akt, ERK1/2 and Smad2/3 pathway in human lung carcinoma A549 cells. Nutr Cancer. 2013; 66(1):140-51. DOI: 10.1080/01635581.2014.853087. View

10.

Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A . miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol. 2011; 193(2):409-24. PMC: 3080260. DOI: 10.1083/jcb.201010100. View

11.

Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi G, Picciotto M . Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol. 2013; 229(1):97-9. DOI: 10.1002/jcp.24422. View

12.

Bar N, Dikstein R . miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One. 2010; 5(5):e10859. PMC: 2877705. DOI: 10.1371/journal.pone.0010859. View

13.

Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang Y . miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy. Tumour Biol. 2014; 35(7):7025-34. DOI: 10.1007/s13277-014-1965-2. View

14.

Xu Q, Pan Y, Li L, Zhou Z, Huang Q, Pang J . MiR-22 is frequently downregulated in medulloblastomas and inhibits cell proliferation via the novel target PAPST1. Brain Pathol. 2014; 24(6):568-83. PMC: 8029063. DOI: 10.1111/bpa.12136. View

15.

Nagaraja A, Creighton C, Yu Z, Zhu H, Gunaratne P, Reid J . A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010; 24(2):447-63. PMC: 2817607. DOI: 10.1210/me.2009-0295. View

16.

Patel J, Appaiah H, Burnett R, Bhat-Nakshatri P, Wang G, Mehta R . Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene. 2010; 30(11):1290-301. DOI: 10.1038/onc.2010.510. View

17.

Li J, Zhang Y, Zhao J, Kong F, Chen Y . Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem. 2011; 357(1-2):31-8. DOI: 10.1007/s11010-011-0872-8. View

18.

Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z . miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 2016; 7:11452. PMC: 5477496. DOI: 10.1038/ncomms11452. View

19.

Guo M, Hu L, Wang Y, Chen P, Huang J, Lu N . miR-22 is down-regulated in gastric cancer, and its overexpression inhibits cell migration and invasion via targeting transcription factor Sp1. Med Oncol. 2013; 30(2):542. DOI: 10.1007/s12032-013-0542-7. View

20.

Zhang C, Wang C, Chen X, Yang C, Li K, Wang J . Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem. 2010; 56(12):1871-9. DOI: 10.1373/clinchem.2010.147553. View